We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stakeholders Share Thoughts on Draft Guidance on Targeted Therapies
Stakeholders Share Thoughts on Draft Guidance on Targeted Therapies
PhRMA, Merck and Illumina offered feedback on the FDA’s draft guidance on the development of treatments that target diseases caused by molecular alterations, requesting the agency provide more details.